Table 2.

Importance of the use of asparaginase comparing different therapeutic protocols.

Study	Overall survival	Regimen
1-DFCI 77-01.39	71 ± 9% vs. 31 ± 11	ASNase vs. Non-ASNase regimen
2-Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).40	93.7% vs. 88.6%	With prolonged vs. without prolonged use of ASNase
3-Amylon et al.41	71.3% vs. 57.8%	High-dose ASNase vs. lower-dose ASNase regimen

Source: Sallan et al.³⁹; Rizzari et al.⁴⁰; Amylon et al.⁴¹.